Search results for: COVID-19 Research
Filter search results
Kahneman’s legacy in health economics
4 April 2024
His research in the 1970s with Amos Tversky resulted in the development of prospect theory, which directly challenged the assumptions that underlie expected utility theory (Kahneman & Tversky, 1979). This…
OHE Lunchtime Seminar: How Cost-Effective are New Cancer Drugs in the U.S.?
18 September 2017, 11:00pm
…is $7853. Frank R. Lichtenberg is Courtney C. Brown Professor of Business at the Columbia University Graduate School of Business; a Research Associate of the National Bureau of Economic Research;…
Inequalities in Dementia: Unveiling the Evidence and Forging a Path Towards Greater Understanding
26 June 2024
…expectation that 1 in 2 people will be affected by dementia during their lifetime, there is a pressing need for further research to inform future policy, research, and service interventions….
Including Carer Quality of Life in Health Technology Evaluation: Are We There Yet?
10 March 2022
…a set of ‘minimum evidence requirements’ were produced, but these were not included in the new manual as further research and stakeholder input is required. This blog provides a summary…
OHE Announces New Trustees and Board Chair
10 January 2022
…she currently serves on the Research Committee for the Office of Health Economics. From January, Professor Kyle will also become Chair of the Research Committee. Professor Werner Brouwer is a…
Capturing the Unexpected Benefits of Medical Research
5 January 2001
…for the organisation of commercial companies but also of university structures and clinical research including the meaningful involvement of patients and the groups that represent them. Reaping the unanticipated rewards…
The Road to Sustainability in the UK and German Biotechnology Industries
1 August 2000
The UK and Germany are the European leaders in biotechnology. They have many more companies and employees in biotechnology, and much greater sums invested in biotechnology research and development (R&D)…
Can We Really Compare and Aggregate PRO Data Between People and Settings? Implications for Multi-Country Clinical Trials and HTA
4 January 2019
…regulatory and reimbursement decisions. Although much progress has been made in this area, there is still scope for further research and improvement. Numerous factors can affect the comparability of PRO…
Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty
1 December 2002
Improving the health and life expectancy of the populations of the less developed countries of the world requires both better access to medicines and research and development (R&D) of new…